All of these molecules participate in cellular activation and inhibition of them after long-term exposure to IFNB1 could suggest a shared downregulatory mechanism between MS patients treated with IFNB1 and SLE patients. The gene discussed is IFNB1; the disease is myeloid sarcoma.